MD Anderson Announces Strategic Collaboration With Denali Therapeutics to Research, Develop Targeted Therapies for Neurodegenerative Diseases
February 22, 2020
February 22, 2020
HOUSTON, Texas, Feb. 22 -- The University of Texas's MD Anderson Cancer Center issued the following news release:
The University of Texas MD Anderson Cancer Center announced a strategic research collaboration with Denali Therapeutics Inc. to develop novel therapies for Alzheimer's and other neurodegenerative diseases. Through this agreement, Denali will collaborate with researchers in the Neurodegeneration Consortium (NDC) at MD Anderson to investigate four therapeutic targets, with . . .
The University of Texas MD Anderson Cancer Center announced a strategic research collaboration with Denali Therapeutics Inc. to develop novel therapies for Alzheimer's and other neurodegenerative diseases. Through this agreement, Denali will collaborate with researchers in the Neurodegeneration Consortium (NDC) at MD Anderson to investigate four therapeutic targets, with . . .